CIBC Asset Management
TEVA icon

CIBC Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

CIBC Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.4M Buy
159,286
+10,902
+7% +$363K 0.01% 503
2026
Q1 		$4.47M Buy
148,384
+11,680
+9% +$376K 0.01% 512
2025
Q4 		$4.27M Buy
136,704
+25,153
+23% +$620K 0.01% 518
2025
Q3 		$2.25M Hold
111,551
– – 0.01% 559
2025
Q2 		$1.87M Sell
111,551
-1,821
-2% -$29.4K 0.01% 582
2025
Q1 		$1.74M Sell
113,372
-6,956
-6% -$124K 0.01% 597
2024
Q4 		$2.65M Buy
120,328
+14,865
+14% +$270K 0.01% 529
2024
Q3 		$1.9M Buy
105,463
+5,713
+6% +$100K 0.01% 587
2024
Q2 		$1.62M Buy
99,750
+3,325
+3% +$51.2K 0.01% 596
2024
Q1 		$1.36M Sell
96,425
-1,607
-2% -$20.3K ﹤0.01% 644
2023
Q4 		$1.02M Sell
98,032
-6,022
-6% -$56.2K ﹤0.01% 656
2023
Q3 		$1.06M Sell
104,054
-244
-0.2% -$2.27K ﹤0.01% 639
2023
Q2 		$785K Hold
104,298
– – ﹤0.01% 681
2023
Q1 		$923K Sell
104,298
-851
-0.8% -$8.41K ﹤0.01% 668
2022
Q4 		$959K Sell
105,149
-6,198
-6% -$54.1K ﹤0.01% 674
2022
Q3 		$899K Sell
111,347
-478
-0.4% -$4.23K ﹤0.01% 685
2022
Q2 		$841K Hold
111,825
– – ﹤0.01% 684
2022
Q1 		$1.05M Buy
111,825
+4,973
+5% +$41.5K ﹤0.01% 685
2021
Q4 		$856K Sell
106,852
-3,517
-3% -$31.7K ﹤0.01% 728
2021
Q3 		$1.07M Buy
110,369
+5,052
+5% +$47.3K ﹤0.01% 662
2021
Q2 		$1.04M Buy
105,317
+6,276
+6% +$66.4K ﹤0.01% 674
2021
Q1 		$1.14M Buy
99,041
+8,567
+9% +$98.2K ﹤0.01% 626
2020
Q4 		$873K Buy
90,474
+1,328
+1% +$12.7K ﹤0.01% 653
2020
Q3 		$803K Buy
89,146
+5,430
+6% +$57.4K ﹤0.01% 626
2020
Q2 		$1.03M Buy
83,716
+4,754
+6% +$53.8K 0.01% 558
2020
Q1 		$709K Buy
78,962
+1,813
+2% +$18.6K 0.01% 574
2019
Q4 		$756K Buy
77,149
+10,636
+16% +$95K ﹤0.01% 657
2019
Q3 		$458K Buy
66,513
+4,128
+7% +$31.6K ﹤0.01% 732
2019
Q2 		$576K Sell
62,385
-1,889
-3% -$22.8K ﹤0.01% 715
2019
Q1 		$1.01M Buy
64,274
+1,581
+3% +$27.9K 0.01% 601
2018
Q4 		$967K Buy
62,693
+5,173
+9% +$106K 0.01% 563
2018
Q3 		$1.24M Hold
57,520
– – 0.01% 545
2018
Q2 		$1.4M Buy
57,520
+1,682
+3% +$34.3K 0.01% 519
2018
Q1 		$954K Sell
55,838
-2,116
-4% -$41.3K 0.01% 593
2017
Q4 		$1.1M Sell
57,954
-7,776
-12% -$117K 0.01% 566
2017
Q3 		$1.16M Buy
65,730
+196
+0.3% +$4.41K 0.01% 542
2017
Q2 		$2.18M Buy
65,534
+178
+0.3% +$5.51K 0.02% 378
2017
Q1 		$2.1M Hold
65,356
– – 0.01% 387
2016
Q4 		$2.37M Buy
+65,356
New +$2.61M 0.02% 353
2016
Q2 		– Sell
-53,643
Closed -$2.87M – 969
2016
Q1 		$2.87M Buy
53,643
+4,038
+8% +$237K 0.02% 293
2015
Q4 		$3.26M Hold
49,605
– – 0.03% 256
2015
Q3 		$2.8M Hold
49,605
– – 0.02% 278
2015
Q2 		$2.93M Buy
49,605
+9,235
+23% +$570K 0.02% 297
2015
Q1 		$2.52M Buy
40,370
+615
+2% +$35.8K 0.02% 329
2014
Q4 		$2.29M Buy
39,755
+2,245
+6% +$125K 0.02% 337
2014
Q3 		$2.02M Buy
37,510
+889
+2% +$47.1K 0.01% 399
2014
Q2 		$1.92M Hold
36,621
– – 0.01% 421
2014
Q1 		$1.94M Sell
36,621
-4,088
-10% -$189K 0.01% 426
2013
Q4 		$1.63M Buy
40,709
+2,600
+7% +$102K 0.01% 443
2013
Q3 		$1.44M Sell
38,109
-200
-0.5% -$7.8K 0.01% 453
2013
Q2 		$1.5M Buy
+38,309
New +$1.49M 0.01% 436

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

CIBC Asset Management's TEVA Position: Q2 2026 in Review

CIBC Asset Management increased its Teva Pharmaceuticals (TEVA) stake by 7.3% in Q2 2026, buying an estimated $363K and bringing the position to 159,286 shares worth $5.4M. The position accounts for 0.01% of the portfolio, ranked #503.

CIBC Asset Management first reported a position in TEVA in Q2 2013 and has held it in 51 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • CIBC Asset Management held 159,286 shares of Teva Pharmaceuticals worth $5.4M as of Q2 2026.
  • CIBC Asset Management bought 10,902 Teva Pharmaceuticals shares in Q2 2026, an estimated $363K.
  • Teva Pharmaceuticals made up 0.01% of CIBC Asset Management's portfolio in Q2 2026, its #503 holding.
  • CIBC Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.